Addressing the issue of cost of treatment in CLL

Stephan Stilgenbauer, MD, PhD of Ulm University, Ulm, Germany, discusses the cost of treatment and collaborations in chronic lymphocytic leukemia (CLL). Novel drugs are of great benefit but they come at a price. There are several developments, trying to combine these agents into regimens that then have to be given only for a finite treatment duration, which is beneficial for the patient. There is also competition now as there are other agents, for example BTK inhibitors, challenging the paradigm of the lead compound. Prof. Stilgenbauer believes this is very good competition as groups combine their forces and companies support the research in this direction, as well as recognizing this as a more sustainable approach. Recorded at the 2016 International Workshop of the German CLL Study Group (GCLLSG) in Cologne, Germany.

Share this video